What is H.C. Wainwright's price target for CDTX?

H.C. Wainwright's latest stated price target for Cidara Therapeutics Inc. (CDTX) is $41, from its action on Jun 18, 2025.

What is H.C. Wainwright's rating on CDTX?

H.C. Wainwright rates CDTX Buy, a bullish rating, as of Jun 18, 2025.

When did H.C. Wainwright last change its view on CDTX?

On Jun 18, 2025, H.C. Wainwright resumes coverage at Buy, price target $41.

Analyst firms · H.C. Wainwright · CDTX

H.C. Wainwright CDTX price target and rating history

Cidara Therapeutics Inc. (CDTX) · Health Care

H.C. Wainwright rates Cidara Therapeutics Inc. (CDTX) Buy with a $41 price target, as of its latest action on Jun 18, 2025. It has published 3 rating actions on CDTX since December 2021, including 1 upgrade and 0 downgrades.

Current rating: Buy
Price target: $41
Median target, all firms: Too few
Actions on CDTX: 3

H.C. Wainwright price target on CDTX

H.C. Wainwright price target on CDTX, each point a stated target, December 2021 to June 2025.

Every H.C. Wainwright rating on CDTX

Jun 18, 2025
ResumeH.C. Wainwright resumes coverage at Buy, price target $41
Aug 14, 2024
UpgradeH.C. Wainwright upgrades to Buy from Neutral, price target $24
Dec 3, 2021
ResumeH.C. Wainwright resumes coverage at Buy, price target $6

How other firms rate CDTX

Each firm's latest rating and stated target in the last 12 months.

Firm	Rating	Price target	Date
Morgan Stanley	Equal-Weight		Nov 17, 2025
RBC Capital Markets	Sector Perform		Nov 17, 2025

Questions about H.C. Wainwright and CDTX

What is H.C. Wainwright's price target for CDTX?: H.C. Wainwright's latest stated price target for Cidara Therapeutics Inc. (CDTX) is $41, from its action on Jun 18, 2025.
What is H.C. Wainwright's rating on CDTX?: H.C. Wainwright rates CDTX Buy, a bullish rating, as of Jun 18, 2025.
When did H.C. Wainwright last change its view on CDTX?: On Jun 18, 2025, H.C. Wainwright resumes coverage at Buy, price target $41.

All H.C. Wainwright ratings CDTX news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.